5Souli M,Wennersten CB,Eliopoulous GM.In vitro activity of BAY 128039, a new fluoroquinolone, against species representative of respiratory tract pathogens[].International Journal of Antimicrobial Agents.1998
6Bradford WZ,Daley CL.Multiple drug-resistant tuberculosis[].Infectious Diseases in Clinical Practice.1998
7Aldridge KE,Ashcraft DS.Comparison of the in vitro activities of BAY 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes[].Antimicrobial Agents and Chemotherapy.1997
8Fass RJ.In vitro activity of Bay 12-8039, a new 8-methoxyquinolone[].Antimicrobial Agents and Chemotherapy.1997
9Visalli MA,Jacobs MR,Appelbaum PC.Antipneumococcal activity of BAY 12-8039, a new quinolone, compared with activities of three other quinolones and four oral beta-lactams[].Antimicrobial Agents and Chemotherapy.1997
10Stass HH,Kubitza D.Study to evaluate the interaction between moxifloxacin ( M ) and iron supplements ( FE )[].Antiinfect Drug Chemother.1998
7Wilks R,Bennett F,Forrester T,et al.Chronic diseases:the nw epidemic[J].West Indian Med J,1998,47(Suppl)4:40-44.
8Lee ET,Cowan LD,Welty TK,et al.All-cause mortality and cardiovascular disease mortality in three American Indian populations,aged 45～74 years,1984～1988.The Strong Heart Study[J].Am J Epidemiol,1998,147:995-1008.
